UY38001A - Compuestos que inhiben las proteínas ras mutantes g12c - Google Patents
Compuestos que inhiben las proteínas ras mutantes g12cInfo
- Publication number
- UY38001A UY38001A UY0001038001A UY38001A UY38001A UY 38001 A UY38001 A UY 38001A UY 0001038001 A UY0001038001 A UY 0001038001A UY 38001 A UY38001 A UY 38001A UY 38001 A UY38001 A UY 38001A
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- inhibit
- mutant ras
- ras proteins
- refers
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102200006538 rs121913530 Human genes 0.000 title 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La memoria descriptiva se refiere a compuestos de Fórmula (I) (I) y sales farmacéuticamente aceptables de los mismos. La memoria descriptiva también se refiere a procesos e intermedios usados para su preparación, a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos proliferativos celulares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762596331P | 2017-12-08 | 2017-12-08 | |
US201862678418P | 2018-05-31 | 2018-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38001A true UY38001A (es) | 2019-05-31 |
Family
ID=64664739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038001A UY38001A (es) | 2017-12-08 | 2018-12-07 | Compuestos que inhiben las proteínas ras mutantes g12c |
Country Status (4)
Country | Link |
---|---|
US (1) | US10597405B2 (es) |
TW (1) | TW201938561A (es) |
UY (1) | UY38001A (es) |
WO (1) | WO2019110751A1 (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7039489B2 (ja) | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12c阻害剤 |
ES2944547T3 (es) | 2017-11-15 | 2023-06-22 | Mirati Therapeutics Inc | Inhibidores de KRas G12C |
US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
US20220152026A1 (en) | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
CN113993860B (zh) * | 2019-06-25 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物 |
CN114195804A (zh) * | 2019-07-30 | 2022-03-18 | 上海凌达生物医药有限公司 | 一类哌啶稠环类化合物、制备方法和用途 |
CN112300173B (zh) * | 2019-07-30 | 2021-10-01 | 上海凌达生物医药有限公司 | 一类含氮多环类化合物、制备方法和用途 |
CA3155066A1 (en) * | 2019-09-20 | 2021-03-25 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
CN112574224A (zh) * | 2019-09-30 | 2021-03-30 | 上海迪诺医药科技有限公司 | Kras g12c抑制剂及其应用 |
CN112707905B (zh) * | 2019-10-25 | 2024-07-02 | 武汉誉祥医药科技有限公司 | 一种三并杂环化合物及其制备方法和用途 |
AU2020372881A1 (en) | 2019-10-28 | 2022-06-09 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
KR20220106765A (ko) * | 2019-10-30 | 2022-07-29 | 젠플리트 테라퓨틱스 (상하이) 아이엔씨. | 치환된 헤테로환형 융합된 환형 화합물, 이의 제조 방법 및 이의 약학적 용도 |
JP2022553858A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
MX2022005360A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
CR20220240A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
CN114980976A (zh) * | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
WO2021150613A1 (en) * | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
GB202001344D0 (en) | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
CN113321654B (zh) * | 2020-02-28 | 2022-05-03 | 上海济煜医药科技有限公司 | 作为激酶抑制剂的稠合吡啶酮类化合物 |
CN115335372B (zh) * | 2020-04-03 | 2024-01-12 | 南京明德新药研发有限公司 | 八氢吡嗪并二氮杂萘啶二酮类化生物 |
CN113527299B (zh) * | 2020-04-18 | 2023-12-29 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物、制备方法和用途 |
EP4144732A4 (en) * | 2020-04-29 | 2024-05-01 | Shanghai Ringene BioPharma Co., Ltd. | BENZOTHIAZOLYL BIARYL COMPOUND, PREPARATION METHOD AND USE THEREOF |
CN115836054A (zh) * | 2020-05-06 | 2023-03-21 | 默沙东有限责任公司 | Il4i1抑制剂和使用方法 |
US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
TWI799871B (zh) * | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | 三環并環類化合物,其製法與醫藥上的用途 |
TW202210633A (zh) | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | 用於治療癌症之dbait分子與kras抑制劑的組合 |
KR20230042600A (ko) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법 |
WO2022037630A1 (zh) * | 2020-08-21 | 2022-02-24 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法及其医药上的用途 |
US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
KR20230081726A (ko) | 2020-09-03 | 2023-06-07 | 레볼루션 메디슨즈, 인크. | Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도 |
JP2023541916A (ja) | 2020-09-15 | 2023-10-04 | レボリューション メディシンズ インコーポレイテッド | がんの治療における、ras阻害剤としてのインドール誘導体 |
WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
JP2023547522A (ja) | 2020-11-06 | 2023-11-10 | タイリガンド バイオサイエンス(シャンハイ)リミテッド | がんの治療のためのKRas阻害剤 |
WO2022133345A1 (en) * | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
WO2022143995A1 (zh) * | 2020-12-31 | 2022-07-07 | 正大天晴药业集团股份有限公司 | 四环类化合物及其医药用途 |
WO2022161489A1 (zh) * | 2021-02-01 | 2022-08-04 | 上海艾力斯医药科技股份有限公司 | 五并杂环类化合物、其制备方法及其应用 |
CN116964056A (zh) * | 2021-03-25 | 2023-10-27 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物盐型、晶型及其应用 |
EP4334321A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras inhibitors |
PE20240089A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
WO2022271658A1 (en) * | 2021-06-23 | 2022-12-29 | Erasca, Inc. | Tricyclic kras inhibitors |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
WO2023280136A1 (zh) * | 2021-07-06 | 2023-01-12 | 浙江海正药业股份有限公司 | 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用 |
KR20240087636A (ko) * | 2021-07-23 | 2024-06-19 | 수저우 잔롱 파마 리미티드 | Kras g12d 억제제 및 이의 용도 |
MX2024000965A (es) | 2021-07-27 | 2024-02-09 | Toray Ind Inc | Medicamento para el tratamiento y/o prevencion de cancer. |
EP4395769A1 (en) | 2021-09-01 | 2024-07-10 | Novartis AG | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
WO2023030517A1 (en) * | 2021-09-06 | 2023-03-09 | Suzhou Zanrong Pharma Limited | Kras g12c inhibitors and uses thereof |
WO2023041059A1 (zh) * | 2021-09-18 | 2023-03-23 | 南京明德新药研发有限公司 | 八氢吡嗪并二氮杂萘啶二酮化合物及其晶型 |
WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
US12030884B2 (en) | 2021-10-01 | 2024-07-09 | Incyte Corporation | Pyrazoloquinoline KRAS inhibitors |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
IL312114A (en) | 2021-10-14 | 2024-06-01 | Incyte Corp | Quinoline compounds as Kras inhibitors |
WO2023072297A1 (zh) * | 2021-11-01 | 2023-05-04 | 江苏恒瑞医药股份有限公司 | 含氮的四环化合物、其制备方法及其在医药上的应用 |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023183755A1 (en) * | 2022-03-21 | 2023-09-28 | Erasca, Inc. | Tricyclic pyrimidones |
CN114605409B (zh) * | 2022-04-01 | 2024-04-02 | 苏州睿尔思科技有限公司 | 一种4-羟基-1,5-萘啶类配体的生产制备方法 |
WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
CN115745854A (zh) * | 2022-07-15 | 2023-03-07 | 浙江奥洋新材料有限公司 | 一种不含肼结构的脂溶性金属离子钝化剂三聚乙二硫醇二苄醚的结构及其合成路线 |
CN115784954A (zh) * | 2022-07-15 | 2023-03-14 | 温州奥洋科技有限公司 | 一种不含肼结构的脂溶性金属离子钝化剂兼三聚乙二硫醇二甲醚的结构及其合成路线 |
GB202212641D0 (en) | 2022-08-31 | 2022-10-12 | Jazz Pharmaceuticals Ireland Ltd | Novel compounds |
WO2024097559A1 (en) * | 2022-10-31 | 2024-05-10 | Beta Pharma, Inc. | 1,5-naphthyridine derivatives as kras oncoprotein inhibitors |
WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201602662YA (en) * | 2013-10-10 | 2016-05-30 | Araxes Pharma Llc | Inhibitors of kras g12c |
EP3197870B1 (en) * | 2014-09-25 | 2020-08-19 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
CA2982360A1 (en) | 2015-04-15 | 2016-10-20 | Liansheng Li | Fused-tricyclic inhibitors of kras and methods of use thereof |
EP3325447A1 (en) * | 2015-07-22 | 2018-05-30 | Araxes Pharma LLC | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
US10875842B2 (en) * | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058768A1 (en) * | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3356353A1 (en) * | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058792A1 (en) * | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
MX2018005967A (es) | 2015-11-16 | 2018-08-29 | Araxes Pharma Llc | Compuestos de quinazolina 2-sustituida que comprenden un grupo heterociclico sustituido y metodos de uso de los mismos. |
JP7039489B2 (ja) * | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12c阻害剤 |
-
2018
- 2018-12-06 TW TW107143817A patent/TW201938561A/zh unknown
- 2018-12-06 WO PCT/EP2018/083853 patent/WO2019110751A1/en active Application Filing
- 2018-12-06 US US16/212,063 patent/US10597405B2/en active Active
- 2018-12-07 UY UY0001038001A patent/UY38001A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW201938561A (zh) | 2019-10-01 |
US10597405B2 (en) | 2020-03-24 |
WO2019110751A1 (en) | 2019-06-13 |
US20190177338A1 (en) | 2019-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
UY38221A (es) | Inhibidores de proteínas ras con g12c mutantes | |
ECSP19028657A (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer | |
UY38602A (es) | Compuestos tricíclicos condensados | |
CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
ECSP16071151A (es) | Inhibidores de dihidropirrolopiridina de ror-gamma | |
CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
UY37098A (es) | Moduladores de ror-gamma | |
GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
UY35275A (es) | Derivados de aminopirazina | |
CO2019008941A2 (es) | Moduladores del receptor de estrógeno | |
AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
UY35344A (es) | Oestra-1,3,5(10),16-tetraeno-3-carboxamidas | |
DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
ECSP18056196A (es) | Derivados de indano | |
UY36958A (es) | Compuestos para administración intracelular | |
DOP2017000138A (es) | Derivados de fumagilol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20231114 |